Financials data is unavailable for this security.
View more
Year on year Kaken Pharmaceutical Co Ltd had relatively flat revenues (72.98bn to 72.04bn), though the company grew net income 47.54% from 5.44bn to 8.03bn.
Gross margin | 53.41% |
---|---|
Net profit margin | 10.08% |
Operating margin | 11.37% |
Return on assets | 4.25% |
---|---|
Return on equity | 5.20% |
Return on investment | 4.88% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Kaken Pharmaceutical Co Ltd fell by 8.94bn. However, the company earned 2.58bn from its operations for a Cash Flow Margin of 3.58%. In addition the company used 5.85bn on investing activities and also paid 5.66bn in financing cash flows.
Cash flow per share | 265.25 |
---|---|
Price/Cash flow per share | 17.92 |
Book value per share | 3,763.43 |
---|---|
Tangible book value per share | 3,568.11 |
More ▼
Balance sheet in JPYView more
Current ratio | 4.72 |
---|---|
Quick ratio | 3.98 |
Total debt/total equity | 0.027 |
---|---|
Total debt/total capital | 0.0263 |
More ▼
Growth rates in JPY
SmartText is unavailable
Div yield(5 year avg) | 3.74% |
---|---|
Div growth rate (5 year) | 0.00% |
Payout ratio (TTM) | 78.20% |
EPS growth(5 years) | -13.76 |
---|---|
EPS (TTM) vs TTM 1 year ago | 42.86 |
More ▼